Serum miRNAs Expression and SNAP-25 Genotype in Alzheimer’s Disease

Simone Agostini1*, Roberta Mancuso1, Gaia Liuzzo1, Elisabetta Bolognesi1, Andrea Saul Costa1, Anna Bianchi1 and Mario Clerici1,2

1IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy, 2Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Introducing the role of microRNAs (miRNAs) in Alzheimer’s disease (AD) and their potential interaction with SNAP-25 polymorphisms.

Recent results suggested the involvement of synaptosomal-associated protein 25 (SNAP-25), a component of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) system, in the pathophysiology of AD. The rs363050 SNAP-25 polymorphism has been associated with cognitive decline and brain atrophy, as well as with the outcome of multistructured rehabilitation in AD patients.

The study investigated the serum expression of miRNAs that bind the SNAP-25 3’ untranslated region (3’UTR) in AD patients (n = 22), mild cognitive impairment (MCI) subjects (n = 22) and age- and sex-matched controls (n = 22). Analysis of results was stratified for the rs363050 SNAP-25 genotype. Results showed that miR-27b-3p, miR-23a-3p and miR181a-5p serum concentration was significantly reduced in rs363050 GG homozygous AD patients. Notably, concentration of these miRNAs was comparable in rs363050 AA homozygous AD patients, MCI and healthy controls (HCs).

Data suggest that miRNAs that bind the SNAP-25 3’UTR region interact with SNAP-25 polymorphisms to influence the neural plasticity typical of AD brains, possibly as a consequence of modulatory activity on SNAP-25 mRNA and/or protein.

Keywords: SNAP-25, microRNA, Alzheimer’s disease, mild cognitive impairment, genotyping, SNP

INTRODUCTION

Alzheimer’s disease (AD) is the most common age-related form of dementia (Alzheimer’s Association, 2014). The etiopathogenesis of the disease is still unknown, and AD is defined as a multifactorial pathology whose development and progression is the result of the combination of several factors (Carreiras et al., 2013). People with a cognitive decline which is more severe than expected, but without the pathological failure typical of AD, are diagnosed as being affected by mild cognitive impairment (MCI; Petersen, 2011; Forlenza et al., 2013).

Recent results suggested the involvement of synaptosomal-associated protein 25 (SNAP-25), a component of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) system, in the pathophysiology of AD. The rs363050 SNAP-25 polymorphism has been associated with cognitive decline and brain atrophy, as well as with the outcome of multistructured rehabilitation in AD patients.
complex involved in the exocytic release of neurotransmitters during synaptic transmission (Antonacci et al., 2016), in neurological disorders, including AD (Noor and Zahid, 2017). Thus, it was shown that: (1) SNAP-25 protein expression is reduced in brains (Shimohama et al., 1997; Greber et al., 1999; Musunuri et al., 2016), and increased in cerebrospinal fluid (Brinkmalm et al., 2014; Sutphen et al., 2018) of AD patients compared to elderly healthy subjects; (2) the SNAP-25 single nucleotide polymorphism (SNP) rs363050 is associated with alterations of categorical fluency and a reduced localized brain activity in AD patients (Guerini et al., 2014), and was shown to be predictive of a worst outcome in AD patients undergoing rehabilitative therapy (Guerini et al., 2016); (3) the overexpression of SNAP-25 in the rat adult dorsal hippocampus leads to the deregulation of memory consolidation (Mckee et al., 2010); and (4) the overexpression of SNAP-25 in rat hippocampal neuron culture cells is associated with synaptic transmission disorders (Owe-Larsson et al., 1999).

MicroRNAs (miRNAs) are short non-coding RNAs (containing about 20–24 nucleotides) involved in mRNA silencing and post-transcriptional regulation of gene expression (Bartel, 2004) via their ability to bind the 3′untranslated region (3′UTR). miRNAs are thus key players in the normal function of cells, and impairments in their modulation, regulation and/or expression are associated with pathologies including tumors (Castro et al., 2017; Drusco and Croce, 2017; Elghoroury et al., 2018; Koutsaki et al., 2017; Mansoori et al., 2017), stroke (Vijayan and Reddy, 2016) and type 2 diabetes mellitus (Liag et al., 2018). A possible role for miRNAs alterations has been postulated in neurological disorders, including AD (Noor and Zahid, 2017).

RESULTS

Serum miRNAs Profiling: Discovery Cohort

Expression profile of 90 miRNAs targeting and putatively binding 3′UTR of SNAP-25 that were selected in silico

| TABLE 1 | Demographic, clinical data and laboratory findings of the study cohort. |
|---------|---------------------------------------------------------------|
|         | AD patients | MCI subjects | Healthy controls |
| N       | 22          | 22          | 22                  |
| Gender (M:F) | 6:16 | 11:11 | 9:13                |
| Age, years | 78.00; 76.00; 70.00; 74.00–81.50 | 22.63–27.68 | 61.25–85.25 |
| MMSE    | 22.15; 24.70; 18.90–24.30 | 22.63–27.68 | 61.25–85.25 |
| ApoE ε-4 carriers (%) | 48 | 18 | 18 | 18 |
| miR-27b-3p (%) | 91 | 100 | 95 | 95 |
| miR-130a-3p (%) | 36 | 35 | 36 | 36 |
| miR-15b-3p (%) | 14 | 32 | 18 | 18 |
| miR-23a-3p (%) | 100 | 100 | 100 | 100 |
| miR-181a-5p (%) | 90; 96 | 1.32; 0.49–1.99 | 0.44–2.81 | 0.44–2.81 |
| miR-361-3p (%) | 65; 77 | 1.64; 0.80–4.33 | 0.62–1.89 | 0.62–1.89 |

Data are reported as median and interquartile range. AD, Alzheimer’s disease; MCI, mild cognitive impairment; M, male; F, female; MMSE, mini mental state evaluation; ApoE, apolipoprotein E, IQR, interquartile range. *p = 0.01 between AD and MCI subjects. **p = 0.02 between AD and MCI subjects.
analysis and are known to be expressed in serum was performed in all the individuals part of the Discovery Cohort (12 HCs; six rs363050 AA genotype vs. six rs363050 GG genotype). Fifty-seven of the 90 miRNAs were detected in serum. Serum relative concentration of six miRNAs was identified as being differentially modulated by the SNAP-25 rs363050 genotype, as their expression ratio was >2.5-fold or <−2.5-fold in both software used (qbase and Qiagen Software): miR-181a-5p, miR-130a-3p, miR-15b-3p, miR27b-3p, miR-361-5p and miR-23a-3p; all these miRNAs were up regulated in GG genotype compared to AA genotype HC.

**Serum miRNAs Expression Validation: Study Cohort**

Results were subsequently validated with single qPCR in a larger population (Study Cohort) that included AD, MCI and HC individuals (*Table 1*).

miR-23a-3p was detected in all individuals whereas miR-15b-3p was observed only in few cases (AD: 14%; MCI: 32%; HCs: 18%). miR-181a-5p was statistically more frequent in MCI (95%) compared to AD patients (65%; *p* = 0.02), whereas HCs had an intermediate frequency (77%). Frequency and fold expression of each miRNA is summarized in *Table 1*.

GG homozygous rs363050 genotype AD patients (ADGG) were characterized by a lower expression of miR-27b-3p, miR-23a-3p and miR181a-5p compared to HCs, regardless of the rs363050 genotypes, as well as to all other groups.

In particular, ADGG were characterized by a significantly lower miR-27b-3p expression (0.23; 0.08–0.71), compared to in AA homozygous AD (ADAA; 2.23; 0.79–3.84; *p* = 0.02) and MCI individuals (MCIAA; 1.63; 0.89–2.89; *p* = 0.03; *Figure 1A*).

Moreover, miR-23a-3p expression reduced as well in ADGG (0.27; 0.05–0.29) compared to all the other groups; this reduction reached statistical significance in comparison with AA homozygous HCs (HCAA; 0.97; 0.56–2.23; *p* = 0.02), ADAA (1.03; 0.30–3.65; *p* = 0.05), MCIAA (1.04; 0.39–1.42; *p* = 0.03), and GG homozygous MCI individuals (MCIGG; 2.14; 0.38–1.01; *p* = 0.03; *Figure 1B*).

Finally, miR-181a-5p expression was lower in ADGG (0.17; 0.02–1.56) compared to all the other groups (vs. ADAA: 2.33; 1.27–2.87; *p* = 0.05; *Figure 1C*). Overall results of miRNAs expression considering the rs363050 genotype are summarized in Supplementary Table S1. No differences were found in relation with sex, apolipoprotein E (*ApoE*) genotype or mini mental state evaluation (MMSE) score.

**DISCUSSION**

AD is a neurodegenerative disorder in which the rate of decline and functional restoration depend on the capacity for neural
plasticity within residual neural tissues (Goldberg et al., 2015); this is at least partially influenced by polymorphisms in genes involved in synaptic transmission, including SNAP-25 (Guerini et al., 2014, 2016). In particular, the rs363050 SNP of SNAP-25 was shown to correlate with brain activity (Guerini et al., 2014) and the outcome of rehabilitation (Guerini et al., 2016) in AD patients.

By binding the 3′UTR region of genes, miRNAs inhibit the translation of mRNA into proteins, thus modulating gene expression (Cai et al., 2009). All the miRNAs analyzed in the present work putatively target and modulate SNAP-25 expression, although miR-27a/b alone has so far been shown to inhibit the activity of SNAP-25 (Machitani et al., 2017). Herein, we describe that the serum expression of miR-27b-3p, miR-23a-3p and miR-181a-5p is significantly reduced in AD patients that are homozygous for the G allele in the rs363050 SNP of SNAP-25. Although it is expressed in an intronic region, rs363050 was shown to modulate the expression of SNAP-25 protein; GG homozygosity, in particular, results in a reduced production of the protein compared to the AA homozygosis (Braida et al., 2015). Importantly, three independent studies detected a very low expression of SNAP-25 protein in the brain of AD patients compared to those of elderly not-AD individuals (Shimohama et al., 1997; Greber et al., 1999; Musunuri et al., 2016). Interestingly, miRNAs miR-27b-3p, miR-23a-3p and miR-181a-5p were also recently shown to be deregulated in serum of patients that underwent ischemic stroke (Wu et al., 2017; Cheng et al., 2018; Vijayan et al., 2018).

Based on these results it is tempting to speculate that in rs363050 GG homozygous AD patients, in whom SNAP-25 protein expression is reduced because of their genetic background, lower amounts of miRNAs that down regulate SNAP-25 expression would be an attempt to bypass such reduced SNAP-25 levels. In MCI individuals this phenomenon is not present possibly because modulation of miRNA expression only characterizes the later phases of dementia.

It is important to note that, as SNAP-25 is more expressed in excitatory neurons than in inhibitory neurons (Frassoni et al., 2005; Garbelli et al., 2008), these miRNAs could have neuroprotective properties; this possibility needs to be analyzed more in-depth.

It is nevertheless important to underline that we analyzed miRNAs expression in serum alone; these data might not reflect what goes on intracellularly, where miRNA-mRNA interactions, and the consequent modulation of gene expression take place.

For these reasons our results need to be validated in a larger cohort, including also rs363050 heterozygous subjects, in which intracellular miRNA expression will need to be investigated. Finally, further experiment based on luciferase assay will be necessary to confirm the interaction between the miRNAs and SNAP-25 3′ UTR region and the effects of such interaction on SNAP-25 expression.

In conclusion, results of this pilot study, although preliminary and requiring to be confirmed by other independent studies with larger cohorts, suggest that the interaction between genetic and epigenetic factors modulate SNAP-25 expression and could contribute to the alterations in synaptic functionality, activity, neuro-plasticity observed in AD.

DATA AVAILABILITY

The raw data supporting the conclusions of this manuscript will be made available by the corresponding author, without undue reservation, to any qualified researcher upon request.

AUTHOR CONTRIBUTIONS

SA and MC designed the experiments and analyzed the data. AB enrolled the subjects and collected the biological samples. SA, GL, EB and AC performed the experiments and data collection. SA, RM and MC interpreted the data and drafted the manuscript.

FUNDING

This research was supported by 2017–2018 Ricerca Corrente, Italian Ministry of Health.

ACKNOWLEDGMENTS

We thank all the subjects enrolled in the study. We are particularly grateful to Mrs. Chiara Sangalli, Mrs. Gabriela Cenuse and Mrs. Barbara Izzo and all the nurses of Department of Neurorehabilitation of IRCCS Santa Maria Nascente for taking care of our patients.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnagi.2019.00052/full#supplementary-material

REFERENCES

Alzheimer’s Association. (2014). 2014 Alzheimer’s disease facts and figures. *Alzheimers Dement.* 10, e47–e92. doi: 10.1016/j.jalz.2014.02.001

Antonucci, F., Corradini, L., Fossati, G., Tomasoni, R., Menna, E., and Matteoli, M. (2016). SNAP-25, a known presynaptic protein with emerging postsynaptic functions. *Front. Synaptic Neurosci.* 8:7. doi: 10.3389/fsyns.2016.00007

Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116, 281–297. doi: 10.1016/S0092-8674(04)00045-5

Braida, D., Guerini, F. R., Ponzoni, L., Corradini, L., De Astis, S., Pattini, L., et al. (2015). Association between SNAP-25 gene polymorphisms and cognition in autism: functional consequences and potential therapeutic strategies. *Transl. Psychiatry* 5:e450. doi: 10.1038/tpp.2014.136

Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausern, L., Minthon, L., et al. (2014). SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. *Mol. Neurodegener.* 9:53. doi: 10.1186/1750-1326-9-53

Cai, Y., Yu, X., Hu, S., and Yu, J. (2009). A brief review on the mechanisms of miRNA regulation. *Genomics Proteomics Bioinformatics* 7, 147–154. doi: 10.1016/S1672-0229(08)60044-3

Carreiras, M. C., Mendes, E., Perry, M. J., Francisco, A. P., and Marco-Contelles, J. (2013). The multifactorial nature of Alzheimer’s disease for...
developing potential therapeutics. Curr. Top. Med. Chem. 13, 1745–1770. doi: 10.2174/15680261313139990135

Castro, D., Moreira, M., Gouveia, A. M., Pozza, D. H., and De Mello, R. A. (2017). MicroRNAs in lung cancer. Oncotarget 8, 81679–81685. doi: 10.18632/oncotarget.20955

Cheng, X., Kan, P., Ma, Z., Wang, Y., Song, W., Huang, C., et al. (2018). Exploring the potential role of miR-148b-3p, miR-151b and miR-27b-3p as biomarkers in acute ischemic stroke. Bioch. Rep. 38:BSR20181033. doi: 10.1042/bsr20181033

Delay, C., Mamedekers, W., and Hébert, S. S. (2012). MicroRNAs in Alzheimer’s disease. Neurobiol. Dis. 46, 285–290. doi: 10.1016/j.nbd.2012.07.005

Elghoroury, E. A., ElDine, H. G., Kamel, S. A., Abdelrahman, A. H., Mohammed, A., Kamel, M. M., et al. (2018). Evaluation of miRNA-21 and miRNA Let-7 as prognostic markers in patients with breast cancer. Clin. Breast Cancer 18, e721–e726. doi: 10.1016/j.clbc.2017.11.022

Forlenza, O. V., Diniz, B. S., Stella, F., Teixeira, A. L., and Gattar, W. F. (2013). Mild cognitive impairment. Part I: clinical characteristics and predictors of dementia. Braz. J. Psychiatry 35, 178–185. doi: 10.1590/1516-4446-2012-3503

Frassoni, C., Inverardi, F., Coco, S., Ortino, B., Grumelli, C., Pozzi, D., et al. (2005). Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience 131, 813–823. doi: 10.1016/j.neuroscience.2004.11.042

Gadek, R., Inverardi, F., Medici, V., Amadeo, A., Verderio, C., Matteoli, M., et al. (2008). Heterogeneous expression of SNAP-25 in rat and human brain. J. Comp. Neurol. 506, 373–386. doi: 10.1002/cne.21505

Goldberg, A., Curtis, C. L., and Klein, J. A. (2015). Linking genes to neurological clinical practice: the genomic basis for Neurorehabilitation. J. Neurol. Phys. Ther. 39, 52–61. doi: 10.1097/np.000000000000066

Greber, S., Lubec, G., Cairns, N., and Fountoulakis, M. (1999). Decreased Grundman, M., Petersen, R. C., Ferris, S. H., Thomas, R. G., Aisen, P. S., Goldberg, A., Curtis, C. L., and Kleim, J. A. (2015). Linking genes to neurological parameters in Alzheimer’s disease. J. Alzheimers Dis. 36, 59–66. doi: 10.3233/jad-150451

Koutsaki, M., Libra, M., Spandidos, D. A., and Zaravinos, A. (2017). The miR-200 family in ovarian cancer. Oncotarget 8, 66629–66640. doi: 10.18632/oncotarget.81679–81685. doi: 10.1006/bbrc.1997.6940

Mizuguchi, H. (2017). MicroRNA miR-27 inhibits adenovirus infection by suppressing the expression of SNAP25 and TXN2. J. Virol. 91:e01599-17. doi: 10.1128/jvi.01599-17

Mansoori, B., Mohammadi, A., Shirjang, S., and Baradaran, B. (2017). MicroRNAs in the diagnosis and treatment of cancer. Immunol. Invest. 46, 880–897. doi: 10.1080/08848099.2017.1377407

McKee, A. G., Loscher, J. S., O’Sullivan, N. C., Chadderton, N., Palfi, A., Battl, L., et al. (2010). AAV-mediated chronic over-expression of SNAP-25 in adult rat dorsal hippocampus impairs memory-associated synaptic plasticity. J. Neurochem. 112, 991–1004. doi: 10.1111/j.1471-4159.2009.05615.x

McKinnon, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34, 939–944. doi: 10.1212/wnl.34.7.939

Musunuri, S., Khoonsari, P. E., Mikus, M., Wetterhall, M., Hägmark-Månberg, A., Lannfelt, L., et al. (2016). Increased levels of extracellular microvesicle markers and decreased levels of endocytic/exocytic proteins in the Alzheimer’s disease brain. J. Alzheimers Dis. 54, 1671–1686. doi: 10.3233/jad-2016-160271

Noor, A., and Zahid, S. (2017). A review of the role of synaptosomal-associated protein 25 (SNAP-25) in neurological disorders. Int. J. Neurosci. 127, 805–811. doi: 10.1080/02755770.2014.941270

Pan, Y., Liu, R., Terpstra, E., Wang, Y., Qiao, F., Wang, J., et al. (2016). Dyregulation and diagnostic potential of microRNA in Alzheimer’s disease. J. Alzheimers Dis. 49, 1–12. doi: 10.3233/jad-150451

Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183–194. doi: 10.1046/j.1365-2768.2004.03188.x

Petersen, R. C. (2011). Clinical practice. N. Engl. J. Med. 364, 2227–2234. doi: 10.1056/NEJMcp0910237

Provost, P. (2010). MicroRNAs a molecular basis for mental retardation, Alzheimer’s and prion diseases. Brain Res. 1338, 58–66. doi: 10.1016/j.brainsci.2010.03.069

Shimohama, S., Kamiya, S., Taniguchi, T., Akagawa, K., and Kimura, J. (1997). Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer’s disease. Biochem. Biophys. Res. Commun. 236, 239–242. doi: 10.1016/j.bbrc.1997.09.040

Surpeth, C. L., McCue, L., Harries, E. M., Xiong, C., Landenstrom, J. H., Holtzman, D. M., et al. (2018). Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease. Alzheimers Dement. 14, 869–879. doi: 10.1017/ade.2018.01.012

Vijayan, M., Kumar, S., Yin, X., Zafer, D., Channa, V., Cengiz, P., et al. (2018). Identification of novel circulatory microRNA signatures linked to patients with ischemic stroke. Hum. Mol. Genet. 27, 2318–2329. doi: 10.1093/hmg/ddy136

Vijayan, M., and Reddy, P. H. (2016). Peripheral biomarkers of stroke: focus on circulatory microRNAs. Biochem. Biophys. Acta 1862, 1984–1993. doi: 10.1016/j.bbadis.2016.08.003

Wang, X., Liu, D., Huang, H. Z., Wang, Z. H., Hou, T. Y., Yang, X., et al. (2018). A novel microRNA-124/PTPN1 signal pathway mediates synaptic and memory deficits in Alzheimer’s disease. Biol. Psychiatry 83, 395–405. doi: 10.1016/j.biopsycho.2017.07.023

Wu, J., Fan, C. L., Ma, L. J., Liu, T., Wang, C., Song, J. X., et al. (2017). Distinctive expression signatures of serum microRNAs in ischemic stroke and transient ischemic attack patients. Thromb. Haemost. 117, 992–1001. doi: 10.1160/TH16-08-0606

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Agostini, Mancuso, Lisuzzo, Bolognesi, Costa, Bianchi and Clerici. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.